FDA
-
-
-
-
-
-
-
BioCryst names Sandeep Menon as chief research and development officer
-
-
-
-
-
-
-
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
-
-
-
-
-
-
-
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
-
-
-
-
-
-
-
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
-
-
-
-
-
-
-
BioCryst Appoints Steve Frank to Board of Directors
-
322,993 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

